Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, published clinical research findings of its anti-ST2 antibody (9MW1911) in healthy subjects as poster presentation at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, the Netherlands from September 27 to October 1, 2025. Currently, a Phase IIb clinical study of 9MW1911 for chronic obstructive pulmonary disease (COPD) is ongoing.

Poster Presentation

Abstract title：First-in-human study of 9MW1911 (an anti-ST2 monoclonal antibody) in healthy volunteers

Abstract Number: 51314

9MW1911 is a novel anti-ST2 monoclonal antibody independently developed through Mabwell's proprietary B-lymphocyte screening platform. It demonstrates high affinity and potent bioactivity. Preclinical studies have revealed its well-characterized mechanism of action – by specifically binding to ST2, it effectively blocks IL-33-induced activation of ST2-mediated signaling pathways, suppressing inflammatory responses to potentially treat various autoimmune diseases.

9MW1911 was safe and well-tolerated in health subjects in the dose range from 25 mg to 1,200 mg. No anti-drug antibodies were detected in any participants. A linear PK profile was observed in the dose range from 100 mg to 1200 mg with total sST2 in serum increased and stabilized, demonstrating sustained target binding. These data support the continued development of 9MW1911 for the therapeutic use in COPD.